Skip to main content
SpringerLink
Log in

Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events

  • Original Article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Background

Susceptibility to cisplatin (CDDP) nephrotoxicity is known to vary between individuals, but the basis of this variation has not been fully elucidated. In the kidney, CDDP is taken up into the renal proximal tubular cells mainly via SLC22A2 organic cation transporter 2 (OCT2) and secreted into lumen via other transporters including SLC47A1 multidrug and toxin extrusion 1 (MATE1). Here, we explore the effect of single-nucleotide polymorphisms (SNPs) at 808G>T in OCT2 and at rs2289669 G>A in MATE1 on CDDP-induced adverse events.

Methods

Fifty-three patients who had been treated with CDDP were enrolled. The plasma concentration of CDDP was measured on days 4 and 7 after treatment. The grade of hematology and nephrotoxicity was evaluated by Common Terminology Criteria for Adverse Events.

Results

In the first treatment cycle, serum creatinine (SCr) levels in the patients with OCT2 808GG and 808GT were increased by 1.43- and 1.19-fold, respectively. In the total treatment cycles, 12 patients (27 %) with 808GG experienced over grade 2 SCr elevation, whereas those with 808GT did not show any apparent nephrotoxicity. The hematological toxicity and plasma concentrations of CDDP showed no difference between patients in both groups. The rs2289669 G>A SNP in MATE1 was not associated with adverse effects and disposition of CDDP.

Conclusion

The 808G>T SNP in OCT2 ameliorated CDDP-induced nephrotoxicity without alteration of disposition, whereas the rs2289669 G>A SNP in MATE1 had no effect on CDDP toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Schrier RW. Cancer therapy and renal injury. J Clin Invest. 2002;110:743–5.

    PubMed  CAS  Google Scholar 

  2. Deng J, Kohda Y, Chiao H, Wang Y, Hu X, Hewitt SM, et al. Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int. 2001;60:2118–28.

    Article  PubMed  CAS  Google Scholar 

  3. Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest. 2002;110:835–42.

    PubMed  CAS  Google Scholar 

  4. Lieberthal W, Triaca V, Levine J. Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol. 1996;270:F700–8.

    PubMed  CAS  Google Scholar 

  5. Pritchard JB, Miller DS. Renal secretion of organic anions and cations. Kidney Int. 1996;49:1649–54.

    Article  PubMed  CAS  Google Scholar 

  6. Inui K, Masuda S, Saito H. Cellular and molecular aspects of drug transport in the kidney. Kidney Int. 2000;58:944–58.

    Article  PubMed  CAS  Google Scholar 

  7. Okuda M, Saito H, Urakami Y, Takano M, Inui K. cDNA cloning and functional expression of a novel rat kidney organic cation transporter, OCT2. Biochem Biophys Res Commun. 1996;224:500–7.

    Article  PubMed  CAS  Google Scholar 

  8. Ohta KY, Inoue K, Hayashi Y, Yuasa H. Molecular identification and functional characterization of rat multidrug and toxin extrusion type transporter 1 as an organic cation/H+ antiporter in the kidney. Drug Metab Dispos. 2006;34:1868–74.

    Article  PubMed  CAS  Google Scholar 

  9. Terada T, Masuda S, Asaka J, Tsuda M, Katsura T, Inui K. Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation antiporter MATE1. Pharm Res. 2006;23:1696–701.

    Article  PubMed  CAS  Google Scholar 

  10. Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci USA. 2005;102:17923–8.

    Article  PubMed  CAS  Google Scholar 

  11. Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther. 2009;86:396–402.

    Article  PubMed  CAS  Google Scholar 

  12. Filipski KK, Loos WJ, Verweij J, Sparreboom A. Interaction of cisplatin with the human organic cation transporter 2. Clin Cancer Res. 2008;14:3875–80.

    Article  PubMed  CAS  Google Scholar 

  13. Ha Choi J, Wah Yee S, Kim MJ, Nguyen L, Ho Lee J, Kang JO, et al. Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1. Pharmacogenet Genomics. 2009;19:770–80.

    Article  PubMed  Google Scholar 

  14. Chen Y, Teranishi K, Li S, Yee SW, Hesselson S, Stryke D, et al. Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. Pharmacogenomics J. 2009;9:127–36.

    Article  PubMed  CAS  Google Scholar 

  15. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes. 2009;58:745–9.

    Article  PubMed  CAS  Google Scholar 

  16. Yokoo K, Murakami R, Matsuzaki T, Yoshitome K, Hamada A, Saito H. Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats. Clin Exp Nephrol. 2009;13:578–84.

    Article  PubMed  CAS  Google Scholar 

  17. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.

    Article  PubMed  CAS  Google Scholar 

  18. Song IS, Shin HJ, Shim EJ, Jung IS, Kim WY, Shon JH, et al. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther. 2008;84:559–62.

    Article  PubMed  CAS  Google Scholar 

  19. Wang ZJ, Yin OQ, Tomlinson B, Chow MS. OCT2 polymorphisms and in vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics. 2008;18:637–45.

    Article  PubMed  CAS  Google Scholar 

  20. Hutchison FN, Perez EA, Gandara DR, Lawrence HJ, Kaysen GA. Renal salt wasting in patients treated with cisplatin. Ann Intern Med. 1988;108:21–5.

    PubMed  CAS  Google Scholar 

  21. Cornelison TL, Reed E. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol. 1993;50:147–58.

    Article  PubMed  CAS  Google Scholar 

  22. Meyer KB, Madias NE. Cisplatin nephrotoxicity. Miner Electrolyte Metab. 1994;20:201–13.

    PubMed  CAS  Google Scholar 

  23. Kim YK, Byun HS, Kim YH, Woo JS, Lee SH. Effect of cisplatin on renal function in rabbits: mechanism of reduced glucose reabsorption. Toxicol Appl Pharmacol. 1995;130:19–26.

    Article  PubMed  CAS  Google Scholar 

  24. Nowak G. Protein kinase C-alpha and ERK1/2 mediate mitochondrial dysfunction, decreases in active Na+ transport, and cisplatin-induced apoptosis in renal cells. J Biol Chem. 2002;277:43377–8823.

    Article  PubMed  CAS  Google Scholar 

  25. Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006;319:879–86.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported in part by a Grant-in-Aid for Scientific Research from Japan Society for the Promotion of Science (JSPS) for Hideyuki Saito (KAKENHI 21390048).

Conflict of interest

All the authors have declared no competing interest.

Author information

Authors and Affiliations

  1. Department of Pharmacy, Kumamoto Red Cross Hospital, 2-1-1 Nagamineminami, Kumamoto, 861-8520, Japan

    Kazufumi Iwata, Keiji Aizawa, Saori Kamitsu, Sachiko Jingami & Eiko Fukunaga

  2. Department of Clinical Pharmaceutical Sciences, Kumamoto University Graduate School of Pharmaceutical Sciences, 5-1 Oe-honmachi, Kumamoto, 862-0973, Japan

    Kazufumi Iwata

  3. Department of Medical Oncology, Kumamoto Red Cross Hospital, 2-1-1 Nagamineminami, Kumamoto, 861-8520, Japan

    Minoru Yoshida

  4. Department of Clinical Pharmaceutical Sciences, Kumamoto University School of Pharmacy, 5-1 Oe-honmachi, Kumamoto, 862-0973, Japan

    Misato Yoshimura

  5. Department of Clinical Pharmaceutical Sciences, Faculty of Life Science, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan

    Akinobu Hamada & Hideyuki Saito

  6. Department of Pharmacy, Kumamoto University Hospital, 1-1-1 Honjo, Kumamoto, 860-8556, Japan

    Akinobu Hamada & Hideyuki Saito

Authors
  1. Kazufumi Iwata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Keiji Aizawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Saori Kamitsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sachiko Jingami
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eiko Fukunaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Minoru Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Misato Yoshimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Akinobu Hamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hideyuki Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideyuki Saito.

About this article

Cite this article

Iwata, K., Aizawa, K., Kamitsu, S. et al. Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events. Clin Exp Nephrol 16, 843–851 (2012). https://doi.org/10.1007/s10157-012-0638-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-012-0638-y

Keywords

Search

Navigation